Qilu Puget Sound Biotherapeutics

Qilu Puget Sound Biotherapeutics is a Seattle-based biotechnology company that serves as the primary U.S. research and development center for Qilu Pharmaceutical. The company specializes in the discovery and development of innovative biologics, with a core focus on oncology and immunology. Utilizing its proprietary MabPair platform, the company develops bispecific antibodies that can simultaneously target multiple pathways, such as PD-1 and CTLA-4. Their pipeline features several advanced candidates currently in global clinical trials, aiming to address significant unmet needs in solid tumors. By integrating Seattle's biotech expertise with Qilu's global manufacturing and commercialization capabilities, the firm accelerates the delivery of next-generation cancer therapies.